Download PDF
Semin Neurol 2010; 30(3): 217-235
DOI: 10.1055/s-0030-1255225
© Thieme Medical Publishers

Brain Metastases

Francois G. Kamar1 , Jerome B. Posner1
  • 1Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York
Further Information

Publication History

Publication Date:
24 June 2010 (online)

    Permissions and Reprints

ABSTRACT

Approximately 10% of patients with cancer develop brain metastases. Some evidence indicates that as techniques for treating systemic tumors improve, the incidence of brain metastases, sequestered as they are behind the blood–brain barrier, is increasing. Although usually appearing late in the course of the disease, a brain metastasis may cause the initial symptoms, before the primary cancer has been identified. The diagnostic and therapeutic approach depends on the number and location of brain lesions and the stage of the cancer. Patients with brain metastases are rarely cured. However, appropriate treatment can improve both the quality and duration of the patient's life. Treatment must be directed not only at the brain metastasis (definitive care), but also at a multitude of other symptoms that plague patients with brain metastases (supportive care). Judicious selection of pharmacologic agents and nonpharmacologic techniques can effectively treat many serious symptoms in patients with brain metastases, but injudicious selection of pharmacologic agents may have side effects and make the patient's quality of life worse. The authors review some aspects of both definitive and supportive care with particular attention to the side effects of some commonly used pharmacologic agents.

KEYWORDS

Brain metastasis - supportive care - corticosteroids - seizures - venous thromboembolism

REFERENCES

  • 1 Posner J B, Chernik N L. Intracranial metastases from systemic cancer.  Adv Neurol. 1978;  19 579-592
    PubMedGoogle Scholar
  • 2 Cairncross J G, Kim J-H, Posner J B. Radiation therapy for brain metastases.  Ann Neurol. 1980;  7(6) 529-541
    CrossrefPubMedGoogle Scholar
  • 3 Lassman A B, DeAngelis L M. Brain metastases.  Neurol Clin. 2003;  21(1) 1-23, vii , vii
    CrossrefPubMedGoogle Scholar
  • 4 DeAngelis L M, Posner J B. Neurologic Complications of Cancer. 2nd ed. New York; Oxford University Press 2009
    PubMedGoogle Scholar
  • 5 Ranjan T, Abrey L E. Current management of metastatic brain disease.  Neurotherapeutics. 2009;  6(3) 598-603
    CrossrefPubMedGoogle Scholar
  • 6 Al-Shamy G, Sawaya R. Management of brain metastases: the indispensable role of surgery.  J Neurooncol. 2009;  92(3) 275-282
    CrossrefPubMedGoogle Scholar
  • 7 Batchelor T T, Byrne T N. Supportive care of brain tumor patients.  Hematol Oncol Clin North Am. 2006;  20(6) 1337-1361
    CrossrefPubMedGoogle Scholar
  • 8 Drappatz J, Schiff D, Kesari S, Norden A D, Wen P Y. Medical management of brain tumor patients.  Neurol Clin. 2007;  25(4) 1035-1071, ix , ix
    CrossrefPubMedGoogle Scholar
  • 9 Barnholtz-Sloan J S, Sloan A E, Davis F G, Vigneau F D, Lai P, Sawaya R E. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.  J Clin Oncol. 2004;  22(14) 2865-2872
    CrossrefPubMedGoogle Scholar
  • 10 Schouten L J, Rutten J, Huveneers H AM, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.  Cancer. 2002;  94(10) 2698-2705
    CrossrefPubMedGoogle Scholar
  • 11 Yonemori K, Tsuta K, Ono M et al.. Disruption of the blood-brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer.  Cancer. 2010;  116(2) 302-308
    CrossrefPubMedGoogle Scholar
  • 12 Smedby K E, Brandt L, Bäcklund M L, Blomqvist P. Brain metastases admissions in Sweden between 1987 and 2006.  Br J Cancer. 2009;  101(11) 1919-1924
    CrossrefPubMedGoogle Scholar
  • 13 Gaspar L, Scott C, Rotman M et al.. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.  Int J Radiat Oncol Biol Phys. 1997;  37(4) 745-751
    Google Scholar
  • 14 Lutterbach J, Bartelt S, Ostertag C. Long-term survival in patients with brain metastases.  J Cancer Res Clin Oncol. 2002;  128(8) 417-425
    CrossrefPubMedGoogle Scholar
  • 15 Patchell R A, Tibbs P A, Walsh J W et al.. A randomized trial of surgery in the treatment of single metastases to the brain.  N Engl J Med. 1990;  322(8) 494-500
    CrossrefPubMedGoogle Scholar
  • 16 Drlicek M, Bodenteich A, Urbanits S, Grisold W. Immunohistochemical panel of antibodies in the diagnosis of brain metastases of the unknown primary.  Pathol Res Pract. 2004;  200(10) 727-734
    CrossrefPubMedGoogle Scholar
  • 17 Chang E L, Hassenbusch III S J, Shiu A S et al.. The role of tumor size in the radiosurgical management of patients with ambiguous brain metastases.  Neurosurgery. 2003;  53(2) 272-280 discussion 280-281
    CrossrefPubMedGoogle Scholar
  • 18 van der Ree T C, Dippel D WJ, Avezaat C JJ, Sillevis Smitt P A, Vecht C J, van den Bent M J. Leptomeningeal metastasis after surgical resection of brain metastases.  J Neurol Neurosurg Psychiatry. 1999;  66(2) 225-227
    CrossrefPubMedGoogle Scholar
  • 19 Narita Y, Shibui S. Strategy of surgery and radiation therapy for brain metastases.  Int J Clin Oncol. 2009;  14(4) 275-280
    CrossrefPubMedGoogle Scholar
  • 20 Suh J H. Stereotactic radiosurgery for the management of brain metastases.  N Engl J Med. 2010;  362(12) 1119-1127
    CrossrefPubMedGoogle Scholar
  • 21 Shu H K, Sneed P K, Shiau C Y et al.. Factors influencing survival after gamma knife radiosurgery for patients with single and multiple brain metastases.  Cancer J Sci Am. 1996;  2 335-342
    PubMedGoogle Scholar
  • 22 van de Pol M, van Aalst V C, Wilmink J T, Twijnstra A. Brain metastases from an unknown primary tumour: which diagnostic procedures are indicated?.  J Neurol Neurosurg Psychiatry. 1996;  61(3) 321-323
    CrossrefPubMedGoogle Scholar
  • 23 Patchell R A, Tibbs P A, Regine W F et al.. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial.  JAMA. 1998;  280(17) 1485-1489
    CrossrefPubMedGoogle Scholar
  • 24 Chang E L, Wefel J S, Hess K R et al.. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.  Lancet Oncol. 2009;  10(11) 1037-1044
    CrossrefPubMedGoogle Scholar
  • 25 Blanchard P, Le Péchoux C. Prophylactic cranial irradiation in lung cancer.  Curr Opin Oncol. 2010;  22(2) 94-101
    CrossrefPubMedGoogle Scholar
  • 26 Huang F, Alrefae M, Langleben A, Roberge D. Prophylactic cranial irradiation in advanced breast cancer: a case for caution.  Int J Radiat Oncol Biol Phys. 2009;  73(3) 752-758
    CrossrefPubMedGoogle Scholar
  • 27 van Breemen M S, Wilms E B, Vecht C J. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management.  Lancet Neurol. 2007;  6(5) 421-430
    CrossrefPubMedGoogle Scholar
  • 28 van Breemen M S, Vecht C J. Optimal seizure management in brain tumor patients.  Curr Neurol Neurosci Rep. 2005;  5(3) 207-213
    CrossrefPubMedGoogle Scholar
  • 29 Corcoran M E. Polypharmacy in the older patient with cancer.  Cancer Control. 1997;  4(5) 419-428
    PubMedGoogle Scholar
  • 30 Toh C H, Wong A M, Wei K C, Ng S H, Wong H F, Wan Y L. Peritumoral edema of meningiomas and metastatic brain tumors: differences in diffusion characteristics evaluated with diffusion-tensor MR imaging.  Neuroradiology. 2007;  49(6) 489-494
    CrossrefPubMedGoogle Scholar
  • 31 Wick W, Küker W. Brain edema in neurooncology: radiological assessment and management.  Onkologie. 2004;  27(3) 261-266
    CrossrefPubMedGoogle Scholar
  • 32 Ryken T C, McDermott M, Robinson P D et al.. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline.  J Neurooncol. 2010;  96(1) 103-114
    CrossrefPubMedGoogle Scholar
  • 33 de Groot J F, Fuller G, Kumar A J et al.. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.  Neuro-oncol. 2010;  12(3) 233-242
    PubMedGoogle Scholar
  • 34 Moliterno J A, Henry E, Pannullo S C. Corticorelin acetate injections for the treatment of peritumoral brain edema.  Expert Opin Investig Drugs. 2009;  18(9) 1413-1419
    CrossrefPubMedGoogle Scholar
  • 35 Lieberman A, LeBrun Y, Glass P et al.. Use of high dose corticosteroids in patients with inoperable brain tumours.  J Neurol Neurosurg Psychiatry. 1977;  40(7) 678-682
    CrossrefPubMedGoogle Scholar
  • 36 Wooldridge J E, Anderson C M, Perry M C. Corticosteroids in advanced cancer.  Oncology (Williston Park). 2001;  15(2) 225-234 discussion 234-236
    PubMedGoogle Scholar
  • 37 Mertens W C, Higby D J, Brown D et al.. Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines.  J Clin Oncol. 2003;  21(7) 1373-1378
    CrossrefPubMedGoogle Scholar
  • 38 Batchelor T T, Taylor L P, Thaler H T, Posner J B, DeAngelis L M. Steroid myopathy in cancer patients.  Neurology. 1997;  48(5) 1234-1238
    PubMedGoogle Scholar
  • 39 Sieb J P, Gillessen T. Iatrogenic and toxic myopathies.  Muscle Nerve. 2003;  27(2) 142-156
    CrossrefPubMedGoogle Scholar
  • 40 Schakman O, Gilson H, Thissen J P. Mechanisms of glucocorticoid-induced myopathy.  J Endocrinol. 2008;  197(1) 1-10
    CrossrefPubMedGoogle Scholar
  • 41 Dirks-Naylor A J, Griffiths C L. Glucocorticoid-induced apoptosis and cellular mechanisms of myopathy.  J Steroid Biochem Mol Biol. 2009;  117(1-3) 1-7
    CrossrefPubMedGoogle Scholar
  • 42 Caplan L, Saag K G. Glucocorticoids and the risk of osteoporosis.  Expert Opin Drug Saf. 2009;  8(1) 33-47
    CrossrefPubMedGoogle Scholar
  • 43 Weldon D. The effects of corticosteroids on bone: osteonecrosis (avascular necrosis of the bone).  Ann Allergy Asthma Immunol. 2009;  103(2) 91-97, quiz 97–100, 133
    CrossrefPubMedGoogle Scholar
  • 44 Nielsen G L, Sørensen H T, Mellemkjoer L et al.. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study.  Am J Med. 2001;  111(7) 541-545
    CrossrefPubMedGoogle Scholar
  • 45 Carson J L, Strom B L, Schinnar R, Duff A, Sim E. The low risk of upper gastrointestinal bleeding in patients dispensed corticosteroids.  Am J Med. 1991;  91(3) 223-228
    CrossrefPubMedGoogle Scholar
  • 46 Metz L M, Sabuda D, Hilsden R J, Enns R, Meddings J B. Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis.  Neurology. 1999;  53(9) 2093-2096
    CrossrefPubMedGoogle Scholar
  • 47 Fadul C E, Lemann W, Thaler H T, Posner J B. Perforation of the gastrointestinal tract in patients receiving steroids for neurologic disease.  Neurology. 1988;  38(3) 348-352
    PubMedGoogle Scholar
  • 48 Weiner H L, Rezai A R, Cooper P R. Sigmoid diverticular perforation in neurosurgical patients receiving high-dose corticosteroids.  Neurosurgery. 1993;  33(1) 40-43
    CrossrefPubMedGoogle Scholar
  • 49 de Quervain D JF, Henke K, Aerni A et al.. Glucocorticoid-induced impairment of declarative memory retrieval is associated with reduced blood flow in the medial temporal lobe.  Eur J Neurosci. 2003;  17(6) 1296-1302
    CrossrefPubMedGoogle Scholar
  • 50 Clore J N, Thurby-Hay L. Glucocorticoid-induced hyperglycemia.  Endocr Pract. 2009;  15(5) 469-474
    CrossrefPubMedGoogle Scholar
  • 51 Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features.  J Neurooncol. 1996;  27(3) 235-240
    CrossrefPubMedGoogle Scholar
  • 52 Sirois F. Steroid psychosis: a review.  Gen Hosp Psychiatry. 2003;  25(1) 27-33
    CrossrefPubMedGoogle Scholar
  • 53 Fietta P, Fietta P, Delsante G. Central nervous system effects of natural and synthetic glucocorticoids.  Psychiatry Clin Neurosci. 2009;  63(5) 613-622
    CrossrefPubMedGoogle Scholar
  • 54 Patten S B, Neutel C I. Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management.  Drug Saf. 2000;  22(2) 111-122
    CrossrefPubMedGoogle Scholar
  • 55 Oberndorfer S, Schmal T, Lahrmann H, Urbanits S, Lindner K, Grisold W. The frequency of seizures in patients with primary brain tumors or cerebral metastases. An evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna.  Wien Klin Wochenschr. 2002;  114(21-22) 911-916
    PubMedGoogle Scholar
  • 56 Vecht C J, Wagner G L, Wilms E B. Interactions between antiepileptic and chemotherapeutic drugs.  Lancet Neurol. 2003;  2(7) 404-409
    CrossrefPubMedGoogle Scholar
  • 57 Yap K Y, Chui W K, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics.  Clin Ther. 2008;  30(8) 1385-1407
    CrossrefPubMedGoogle Scholar
  • 58 Maschio M, Dinapoli L, Gomellini S et al.. Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy.  J Neurooncol. 2009;  , November 24 (Epub ahead of print)
    PubMedGoogle Scholar
  • 59 Mikkelsen T, Paleologos N A, Robinson P D et al.. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline.  J Neurooncol. 2010;  96(1) 97-102
    CrossrefPubMedGoogle Scholar
  • 60 Glantz M J, Cole B F, Forsyth P A Report of the Quality Standards Subcommittee of the American Academy of Neurology et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.  Neurology. 2000;  54(10) 1886-1893
    CrossrefPubMedGoogle Scholar
  • 61 Mamon H J, Wen P Y, Burns A C, Loeffler J S. Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy.  Epilepsia. 1999;  40(3) 341-344
    CrossrefPubMedGoogle Scholar
  • 62 Temkin N R. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials.  Epilepsia. 2001;  42(4) 515-524
    CrossrefPubMedGoogle Scholar
  • 63 Foy P M, Chadwick D W, Rajgopalan N, Johnson A L, Shaw M D. Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy?.  J Neurol Neurosurg Psychiatry. 1992;  55(9) 753-757
    CrossrefPubMedGoogle Scholar
  • 64 van Breemen M S, Rijsman R M, Taphoorn M J, Walchenbach R, Zwinkels H, Vecht C J. Efficacy of anti-epileptic drugs in patients with gliomas and seizures.  J Neurol. 2009;  256(9) 1519-1526
    CrossrefPubMedGoogle Scholar
  • 65 Rodrigues C A, Ferrarotto R, Filho R K, Novis Y A, Hoff P M. Venous thromboembolism and cancer: a systematic review.  J Thromb Thrombolysis. 2010; February 6;  , (Epub ahead of print)
    PubMedGoogle Scholar
  • 66 Lee A Y, Levine M N. Venous thromboembolism and cancer: risks and outcomes.  Circulation. 2003;  107 117-121
    CrossrefPubMedGoogle Scholar
  • 67 Chan A T, Atiemo A, Diran L K et al.. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis.  J Thromb Thrombolysis. 1999;  8(2) 139-142
    CrossrefPubMedGoogle Scholar
  • 68 Sawaya R, Zuccarello M, Elkalliny M, Nishiyama H. Postoperative venous thromboembolism and brain tumors: Part I. Clinical profile.  J Neurooncol. 1992;  14(2) 119-125
    PubMedGoogle Scholar
  • 69 Goldhaber S Z, Dunn K, Gerhard-Herman M, Park J K, Black P M. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis.  Chest. 2002;  122(6) 1933-1937
    CrossrefPubMedGoogle Scholar
  • 70 ten Cate-Hoek A J, Prins M H. Low molecular weight heparins in cancer. Management and prevention of venous thromboembolism in patients with malignancies.  Thromb Res. 2008;  122(5) 584-598
    CrossrefPubMedGoogle Scholar
  • 71 Schulman S, Kearon C, Kakkar A K RE-COVER Study Group et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism.  N Engl J Med. 2009;  361(24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 72 Levine M N. New antithrombotic drugs: potential for use in oncology.  J Clin Oncol. 2009;  27(29) 4912-4918
    CrossrefPubMedGoogle Scholar
  • 73 Lassen M R, Raskob G E, Gallus A, Pineo G, Chen D, Hornick P. ADVANCE-2 investigators . Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.  Lancet. 2010;  375(9717) 807-815
    CrossrefPubMedGoogle Scholar
  • 74 Lee A Y, Levine M N, Baker R I Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.  N Engl J Med. 2003;  349(2) 146-153
    CrossrefPubMedGoogle Scholar
  • 75 Wells P S, Anderson D R, Rodger M et al.. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis.  N Engl J Med. 2003;  349(13) 1227-1235
    Google Scholar
  • 76 Schiff D, DeAngelis L M. Therapy of venous thromboembolism in patients with brain metastases.  Cancer. 1994;  73(2) 493-498
    CrossrefPubMedGoogle Scholar
  • 77 Young T, Tang H, Hughes R. Vena caval filters for the prevention of pulmonary embolism.  Cochrane Database Syst Rev. 2010;  2 CD006212
    PubMedGoogle Scholar
  • 78 Flaim A, Brennan M, Safranek S. Do endovascular filters prevent PE as effectively as anticoagulants in patients with DVT?.  J Fam Pract. 2010;  59(2) 121-122
    PubMedGoogle Scholar
  • 79 Tisdale M J. Cancer cachexia.  Curr Opin Gastroenterol. 2010;  26(2) 146-151
    CrossrefPubMedGoogle Scholar
  • 80 Chipkevitch E. Brain tumors and anorexia nervosa syndrome.  Brain Dev. 1994;  16(3) 175-179 discussion 180-182 discussion
    CrossrefPubMedGoogle Scholar
  • 81 Takahashi T, Kazama Y, Shimizu H, Yoshimoto M, Tsujisaki M, Imai K. Brain metastases of malignant melanoma showing unbalanced whole arm chromosomal translocations der (8; 14) (q10; q10) and der (11; 15) (q10; q10) in a Japanese patient.  Intern Med. 2001;  40(9) 956-960
    CrossrefPubMedGoogle Scholar
  • 82 Laviano A, Meguid M M, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies.  Lancet Oncol. 2003;  4(11) 686-694
    CrossrefPubMedGoogle Scholar
  • 83 Hong J H, Omur-Ozbek P, Stanek B T et al.. Taste and odor abnormalities in cancer patients.  J Support Oncol. 2009;  7(2) 58-65
    PubMedGoogle Scholar
  • 84 Fehm-Wolfsdorf G, Scheible E, Zenz H, Born J, Fehm H L. Taste thresholds in man are differentially influenced by hydrocortisone and dexamethasone.  Psychoneuroendocrinology. 1989;  14(6) 433-440
    CrossrefPubMedGoogle Scholar
  • 85 Ishimaru T, Miwa T, Nomura M, Iwato M, Furukawa M. Reversible hyposmia caused by intracranial tumour.  J Laryngol Otol. 1999;  113(8) 750-753
    PubMedGoogle Scholar
  • 86 Sagar S M, Thomas R J, Loverock L T, Spittle M F. Olfactory sensations produced by high-energy photon irradiation of the olfactory receptor mucosa in humans.  Int J Radiat Oncol Biol Phys. 1991;  20(4) 771-776
    PubMedGoogle Scholar
  • 87 Vissink A, Jansma J, Spijkervet F K, Burlage F R, Coppes R P. Oral sequelae of head and neck radiotherapy.  Crit Rev Oral Biol Med. 2003;  14(3) 199-212
    CrossrefPubMedGoogle Scholar
  • 88 Scalera G. Effects of conditioned food aversions on nutritional behavior in humans.  Nutr Neurosci. 2002;  5(3) 159-188
    CrossrefPubMedGoogle Scholar
  • 89 Baracos V E. Cancer-associated cachexia and underlying biological mechanisms.  Annu Rev Nutr. 2006;  26 435-461
    CrossrefPubMedGoogle Scholar
  • 90 Cerchietti L C, Navigante A H, Peluffo G D et al.. Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study.  J Pain Symptom Manage. 2004;  27(1) 85-95
    CrossrefPubMedGoogle Scholar
  • 91 Sato K, Onuma E, Yocum R C, Ogata E. Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody.  Semin Oncol. 2003;  30(5, Suppl 16) 167-173
    CrossrefPubMedGoogle Scholar
  • 92 Del Fabbro E, Dalal S, Bruera E. Symptom control in palliative care—Part II: cachexia/anorexia and fatigue.  J Palliat Med. 2006;  9(2) 409-421
    CrossrefPubMedGoogle Scholar
  • 93 Wood G J, Shega J W, Lynch B, Von Roenn J H. Management of intractable nausea and vomiting in patients at the end of life: “I was feeling nauseous all of the time … nothing was working”.  JAMA. 2007;  298(10) 1196-1207
    CrossrefPubMedGoogle Scholar
  • 94 Minami M, Endo T, Hirafuji M et al.. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity.  Pharmacol Ther. 2003;  99(2) 149-165
    CrossrefPubMedGoogle Scholar
  • 95 Keeley P W. Nausea and vomiting in people with cancer and other chronic diseases. Clin Evid (Online) January 13, 2009
    PubMedGoogle Scholar
  • 96 Tremblay P B, Kaiser R, Sezer O et al.. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients.  J Clin Oncol. 2003;  21(11) 2147-2155
    CrossrefPubMedGoogle Scholar
  • 97 Henzi I, Walder B, Tramèr M R. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review.  Anesth Analg. 2000;  90(1) 186-194
    CrossrefPubMedGoogle Scholar
  • 98 Potter J, Hami F, Bryan T, Quigley C. Symptoms in 400 patients referred to palliative care services: prevalence and patterns.  Palliat Med. 2003;  17(4) 310-314
    CrossrefPubMedGoogle Scholar
  • 99 Walsh D, Rybicki L. Symptom clustering in advanced cancer.  Support Care Cancer. 2006;  14(8) 831-836
    CrossrefPubMedGoogle Scholar
  • 100 Reville B, Axelrod D, Maury R. Palliative care for the cancer patient.  Prim Care. 2009;  36(4) 781-810
    PubMedGoogle Scholar
  • 101 Clemens K E, Klaschik E. Management of constipation in palliative care patients.  Curr Opin Support Palliat Care. 2008;  2(1) 22-27
    CrossrefPubMedGoogle Scholar
  • 102 Clemens K E, Klaschik E. Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide.  Ther Clin Risk Manag. 2010;  6 77-82
    PubMedGoogle Scholar
  • 103 Meyers C A, Smith J A, Bezjak A et al.. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.  J Clin Oncol. 2004;  22(1) 157-165
    CrossrefPubMedGoogle Scholar
  • 104 Soussain C, Ricard D, Fike J R, Mazeron J J, Psimaras D, Delattre J Y. CNS complications of radiotherapy and chemotherapy.  Lancet. 2009;  374(9701) 1639-1651
    CrossrefPubMedGoogle Scholar
  • 105 Ricard D, Taillia H, Renard J L. Brain damage from anticancer treatments in adults.  Curr Opin Oncol. 2009;  21(6) 559-565
    CrossrefPubMedGoogle Scholar
  • 106 Vardy J, Wefel J S, Ahles T, Tannock I F, Schagen S B. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop.  Ann Oncol. 2008;  19(4) 623-629
    CrossrefPubMedGoogle Scholar
  • 107 Snyderman D, Wynn D. Depression in cancer patients.  Prim Care. 2009;  36(4) 703-719
    PubMedGoogle Scholar
  • 108 Hardy S E. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults.  Am J Geriatr Pharmacother. 2009;  7(1) 34-59
    CrossrefPubMedGoogle Scholar
  • 109 Kohli S, Fisher S G, Tra Y et al.. The effect of modafinil on cognitive function in breast cancer survivors.  Cancer. 2009;  115(12) 2605-2616
    CrossrefPubMedGoogle Scholar
  • 110 Hofman M, Ryan J L, Figueroa-Moseley C D, Jean-Pierre P, Morrow G R. Cancer-related fatigue: the scale of the problem.  Oncologist. 2007;  12(Suppl 1) 4-10
    CrossrefPubMedGoogle Scholar
  • 111 Pelletier G, Verhoef M J, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues.  J Neurooncol. 2002;  57(1) 41-49
    CrossrefPubMedGoogle Scholar
  • 112 Stasi R, Abriani L, Beccaglia P et al.. Cancer-related fatigue: evolving concepts in evaluation and treatment.  Cancer. 2003;  98 1786-1801
    CrossrefPubMedGoogle Scholar
  • 113 Ryan J L, Carroll J K, Ryan E P, Mustian K M, Fiscella K, Morrow G R. Mechanisms of cancer-related fatigue.  Oncologist. 2007;  12(Suppl 1) 22-34
    CrossrefPubMedGoogle Scholar
  • 114 Carroll J K, Kohli S, Mustian K M, Roscoe J A, Morrow G R. Pharmacologic treatment of cancer-related fatigue.  Oncologist. 2007;  12(Suppl 1) 43-51
    CrossrefPubMedGoogle Scholar
  • 115 Mustian K M, Morrow G R, Carroll J K, Figueroa-Moseley C D, Jean-Pierre P, Williams G C. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue.  Oncologist. 2007;  12(Suppl 1) 52-67
    CrossrefPubMedGoogle Scholar
  • 116 Forsyth P A, Posner J B. Headaches in patients with brain tumors: a study of 111 patients.  Neurology. 1993;  43(9) 1678-1683
    PubMedGoogle Scholar
  • 117 Hamilton W, Kernick D. Clinical features of primary brain tumours: a case-control study using electronic primary care records.  Br J Gen Pract. 2007;  57(542) 695-699
    PubMedGoogle Scholar
  • 118 Argyriou A A, Chroni E, Polychronopoulos P et al.. Headache characteristics and brain metastases prediction in cancer patients.  Eur J Cancer Care (Engl). 2006;  15(1) 90-95
    CrossrefPubMedGoogle Scholar
  • 119 Larner A J. Not all morning headaches are due to brain tumours.  Pract Neurol. 2009;  9(2) 80-84
    CrossrefPubMedGoogle Scholar
  • 120 Bush S H, Bruera E. The assessment and management of delirium in cancer patients.  Oncologist. 2009;  14(10) 1039-1049
    CrossrefPubMedGoogle Scholar
  • 121 Tuma R, DeAngelis L M. Altered mental status in patients with cancer.  Arch Neurol. 2000;  57(12) 1727-1731
    CrossrefPubMedGoogle Scholar
  • 122 Ljubisavljevic V, Kelly B. Risk factors for development of delirium among oncology patients.  Gen Hosp Psychiatry. 2003;  25(5) 345-352
    CrossrefPubMedGoogle Scholar
  • 123 Inouye S K, van Dyck C H, Alessi C A, Balkin S, Siegal A P, Horwitz R I. Clarifying confusion: the confusion assessment method. A new method for detection of delirium.  Ann Intern Med. 1990;  113(12) 941-948
    CrossrefPubMedGoogle Scholar
  • 124 Caraceni A, Simonetti F. Palliating delirium in patients with cancer.  Lancet Oncol. 2009;  10(2) 164-172
    CrossrefPubMedGoogle Scholar
  • 125 Drislane F W. Nonconvulsive status epilepticus in patients with cancer.  Clin Neurol Neurosurg. 1994;  96(4) 314-318
    CrossrefPubMedGoogle Scholar
  • 126 Towne A R, Waterhouse E J, Boggs J G et al.. Prevalence of nonconvulsive status epilepticus in comatose patients.  Neurology. 2000;  54(2) 340-345
    CrossrefPubMedGoogle Scholar
  • 127 Primavera A, Audenino D, Cocito L. Ifosfamide encephalopathy and nonconvulsive status epilepticus.  Can J Neurol Sci. 2002;  29(2) 180-183
    PubMedGoogle Scholar
  • 128 Martínez-Rodríguez J E, Barriga F J, Santamaria J et al.. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure.  Am J Med. 2001;  111(2) 115-119
    CrossrefPubMedGoogle Scholar
  • 129 Breitbart W, Alici Y. Agitation and delirium at the end of life: “We couldn't manage him”.  JAMA. 2008;  300(24) 2898-2910, E1
    CrossrefPubMedGoogle Scholar
  • 130 Vento S, Cainelli F. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment.  Lancet Oncol. 2003;  4(10) 595-604
    CrossrefPubMedGoogle Scholar
  • 131 Mahindra A K, Grossman S A. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors.  J Neurooncol. 2003;  63(3) 263-270
    CrossrefPubMedGoogle Scholar
  • 132 Pasquale T R, Tan J S. Nonantimicrobial effects of antibacterial agents.  Clin Infect Dis. 2005;  40(1) 127-135
    CrossrefPubMedGoogle Scholar
  • 133 Cunha B A. Antibiotic side effects.  Med Clin North Am. 2001;  85(1) 149-185
    Google Scholar
  • 134 Thomas R J. Neurotoxicity of antibacterial therapy.  South Med J. 1994;  87(9) 869-874
    CrossrefPubMedGoogle Scholar
  • 135 Pai M P, Momary K M, Rodvold K A. Antibiotic drug interactions.  Med Clin North Am. 2006;  90(6) 1223-1255
    CrossrefPubMedGoogle Scholar

Jerome B PosnerM.D. 

Department of Neurology, Memorial Sloan-Kettering Cancer Center

1275 York Avenue, New York, NY 10065

Email: posnerj@mskcc.org